Journal of Clinical Oncology
Articles in this Issue
Vedolizumab or infliximab: Treatment option in immune checkpoint inhibitor–induced colitis.
2667 Background: ICI use is linked to severe gastrointestinal (GI) immune-related adverse events (irAEs), which affect morbidity and mortality and often r...
Clinical and molecular outcomes of gastrointestinal malignancies treated with early phase studies: A retrospective single-center experience.
e16433 Background: Several clinical and molecular characteristics, including oncogenic alterations, tumor mutation burden (TMB), mismatch repair (MMR) sta...
Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.
e16264 Background: Adenocarcinoma arising from the ampulla of Vater is an extremely rare neoplasm, and there is limited data regarding frontline therapy f...
Brazilian Society of Surgical Oncology: Realities and challenges of surgical oncologists in palliative care practice.
e13553 Background: Palliative care (PC) enhances symptom control, quality of life (QoL), and decision-making in oncology. Despite its relevance to surgica...
Cox models vs. machine learning for survival prediction: Do traditional approaches still hold their ground?
e13647 Background: Sarculator, a Cox model-based nomogram, has been widely used for survival predictions in patients with extremity soft tissue sarcomas (...
Clinical characteristics and recurrence patterns in Hispanic vs. non-Hispanic patients with leiomyosarcoma: Findings from a retrospective single-center cohort study.
e23544 Background: Leiomyosarcoma (LMS), a rare and aggressive malignancy, commonly arises from the uterus, retroperitoneum, and extremities, carrying a p...
Predictors of prolonged hospital length of stay following craniotomy for brain tumor resection: A systematic review and meta-analysis.
e23245 Background: Hospital length of stay (LOS) is a crucial indicator for assessing the quality of care. Identifying predictors of prolonged hospital LO...
A novel aptamer-based non-invasive test for lung cancer: A proof-of-concept.
8033 Background: Lung cancer (LC) is the leading cause of cancer-related mortality, primarily due to late-stage diagnoses. Low-dose computed tomography (L...
Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM).
7555 Background: S100A9, a protein produced by myeloid-derived suppressor cells in the bone marrow microenvironment, promo...
Enhancing glioblastoma therapy with a recombinant Newcastle disease virus harboring the PTEN gene.
e15185 Background: Glioblastoma (GBM), a highly aggressive brain tumor, is challenging to treat due to its resistance to conventional therapies and the re...
Patient-specific factors as predictors of chemotherapy-induced nausea and vomiting: Insights from a lower-middle-income setting.
e24075 Background: Chemotherapy-induced nausea and vomiting (CINV) affects approximately 40% of cancer patients, despite t...
Association of socioeconomic deprivation with clinical outcomes among hospitalized patients with cancer.
e23107 Background: Individuals with cancer often require hospitalization to address acute concerns. Structural barriers, such as socioeconomic deprivation...
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.
TPS615 Background: The TAILORx and RxPONDER trials demonstrated that RS identifies many postmenopausal pts with node-neg and node-pos BC and RS ≤25, who d...
Survival and treatment outcomes in head and neck cancer patients with brain metastases (HNC-BM): A national analysis.
e14009 Background: Brain metastases (BM) in head and neck cancer (HNC) are uncommon, occurring in 0.03–0.4% of cases and linked to poor survival outcomes....
Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours.
TPS4224 Background: PRRT is a standard therapeutic option for patients with metastatic well-differentiated somatostatin receptor-positive gastroenteropanc...
Real-world cardiovascular outcomes of carfilzomib in relapsed or refractory multiple myeloma.
e19524 Background: Carfilzomib, a second-generation proteasome inhibitor, has emerged as one of the therapeutic agents in the treatment of relapsed or ref...
A real-world comparative analysis of cardiovascular (CV) safety and time to next treatment (TTNT) with acalabrutinib versus ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
e23280 Background: Bruton tyrosine kinase inhibitors (BTKis) are standard of care in CLL/SLL. However, BTKis, especially ibrutinib, are associated with CV...
The report of a single-arm, single-center, retrospective analysis investigating PD-L1 plus chemotherapy as adjuvant therapy in resected biliary tract cancer.
e16322 Background: Biliary tract cancer (BTC) is a heterogeneous group of diseases with dismal prognosis. The TOPAZ-1 phase III trial a survival benefit w...
Association between pre-transplant biological aging markers and clinical outcomes in allogeneic hematopoietic cell transplant recipients.
6562 Background: Cancer and its treatments can accelerate the aging process, placing survivors at increased risk for poor outcomes. Hematopoietic cell tra...
Whole-genome sequencing of biliary tract cancer: Uncovering the genomic origins of evolutionary trajectories.
4116 Background: Biliary tract cancers (BTC) are rare, highly aggressive malignancies with limited treatment options, leading to consistently poor outcome...
Efficacy and safety of second-line therapy with serplulimab, lenvatinib, and paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) for whom immunochemotherapy failed: A multicenter, single-arm, phase II trial (STILL).
e16075 Background: PD-1 antibodies in combination with chemotherapy have become the standard first-line treatment for advanced GC/GEJC. However, it is unk...
Pre-transplant measures of geriatric assessment domains and outcomes of allogeneic hematopoietic cell transplantation in adults aged 75 and older.
6563 Background: The upper age limit for allogeneic hematopoietic cell transplantation (HCT) has risen over time, yet prior studies indicate worse outcome...
Equitable access for management of pre-invasive cervical disease.
e17528 Background: The goal of this study was to evaluate the utilization and effectiveness of Nurse Practitioners (NPs) in under-resourced areas as a met...
A phase 1 first-in-human study of the novel anti-LLT1 antibody (ZM008) alone and in combination with anti-PD1 antibody in patients with advanced solid tumors.
TPS2688 Background: ZM008 is a first-in-class, fully human, IgG1 monoclonal antibody targeting the LLT1 antigen. It disrupts the interaction of LLT1-CD161...
Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with advanced solid tumors: Results from two dose-escalation cohorts of the phase 1b STELLAR 002 study.
3101 Background: Zanza (XL092) is a novel, multi-targeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR, MET, and TAM kinases. In tumor models, zanz...